[68Ga]Pentixafor PET/CT 用于新诊断多发性骨髓瘤分期与预后评估:与[18F]FDG PET/CT 的比较
回顾性纳入 55 例新诊断多发性骨髓瘤患者,按 Durie-Salmon PLUS 分期系统基于[68Ga]Pentixafor PET/CT 与[18F]FDG PET/CT 分别分期,并比较 R-ISS。Pentixafor PET/CT 分期可区分不同分期间的 PFS,预测 2 年 PFS 的 AUC 显著高于 Pentixafor PET、FDG PET 及 R-ISS。
要点
- Pentixafor PET 较 FDG PET 使 26 例升期、4 例降期(P=0.001),加入低剂量 CT 后各期例数差异无统计学意义(P=0.091)。
- Pentixafor PET/CT 分期可区分 I vs II、I vs III、II vs III 的 PFS(均 P<0.05),FDG PET/CT 仅 I 与 III 中位 PFS 有差异(P=0.021)。
- 预测 2 年 PFS 的 AUC:Pentixafor PET/CT 0.923 显著高于 Pentixafor PET 0.821、FDG PET 0.752 及 R-ISS 0.776。
核心结论
- 基于[68Ga]Pentixafor PET/CT 的分期在预测新诊断多发性骨髓瘤患者疾病进展方面具有较大潜力。
研究设计与样本
- 回顾性纳入接受[68Ga]Pentixafor 与[18F]FDG PET/CT 显像的患者,共评估 55 例多发性骨髓瘤患者。
主要发现
- Pentixafor PET 与 FDG PET 相比,25 例分期相同、26 例升期、4 例降期(P=0.001)。
- 考虑低剂量 CT 数据后,Pentixafor PET/CT 与 FDG PET/CT 各期患者例数差异无统计学意义(P=0.091)。
- Pentixafor PET/CT 分期可区分不同分期患者的 PFS(I vs II、I vs III、II vs III,均 P<0.05)。
- FDG PET/CT 仅在 I 期与 III 期中位 PFS 间有差异(P=0.021)。
- 按 R-ISS 分期,III 期中位 PFS 显著低于 I 期和 II 期(P=0.008 和 0.035)。
关键数值与推荐
- 预测 2 年 PFS 的 AUC:Pentixafor PET/CT 0.923 vs Pentixafor PET 0.821(P=0.002)。
- 预测 2 年 PFS 的 AUC:Pentixafor PET/CT 0.923 vs FDG PET 0.752(P=0.002)。
- 预测 2 年 PFS 的 AUC:Pentixafor PET/CT 0.923 vs R-ISS 0.776(P=0.005)。
临床怎么用
- 原文结论认为基于[68Ga]Pentixafor PET/CT 的分期在预测新诊断多发性骨髓瘤患者疾病进展方面具有较大潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the prognostic performance of [68Ga]Pentixafor PET/CT at baseline for staging of patients with newly diagnosed multiple myeloma (MM) and to compare it with [18F]FDG PET/CT and the Revised-International Staging System (R-ISS). METHODS: Patients who underwent [68Ga]Pentixafor and [18F]FDG PET/CT imaging were retrospectively included. Patient staging was performed according to the Durie-Salmon PLUS staging system based on [68Ga]Pentixafor PET/CT and [18F]FDG PET/CT images, and the R-ISS. Progression-free survival (PFS) at patient follow-up was estimated using the Kaplan-Meier estimator and compared using the log-rank test. Area under the receiver operating characteristic curve (AUC) was calculated to assess predictive performance. RESULTS: Fifty-five MM patients were evaluated. Compared with [18F]FDG PET, [68Ga]Pentixafor PET detected 25 patients as the same stage, while 26 patients were upstaged and 4 patients were downstaged (P = 0.001). After considering the low-dose CT data, there was no statistically significant difference in the number of patients classified in each stage using [68Ga]Pentixafor PET/CT and [18F]FDG PET/CT (P = 0.091). [68Ga]Pentixafor PET/CT-based staging discriminated PFS outcomes in patients with different disease stages (stage I vs. stage II, stage I vs. stage III, and stage II vs. stage III; all P < 0.05), whereas for [18F]FDG PET/CT, there was only a difference in median PFS between stage I and III (P = 0.021). When staged by R-ISS, the median PFS for stage III was significantly lower than that for stage I and II (P = 0.008 and 0.035, respectively). When predicting 2-year PFS based on staging, the AUC of [68Ga]Pentixafor PET/CT was significantly higher than that of [68Ga]Pentixafor PET (0.923 vs. 0.821, P = 0.002), [18F]FDG PET (0.923 vs. 0.752 P = 0.002), and R-ISS (0.923 vs. 0.776, P = 0.005). CONCLUSIONS: [68Ga]Pentixafor PET/CT-based staging possesses substantial potential to predict disease progression in newly diagnosed MM patients.
引用
- Chen Z, Yang A, Chen A, et al. [68Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2024. PMID: 38286937. doi:10.1007/s00259-024-06621-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。